By omuat.com | June 21, 2026
A Devastating Gap in Early Lung Cancer Care
Imagine surviving lung cancer surgery, hearing the surgeon say “we got it all” — and then living with the dread that the tumor could return at any moment. For patients with a rare subtype of lung cancer called RET fusion-positive non-small cell lung cancer (NSCLC), this was reality. After curative surgery, there was no approved targeted therapy to prevent recurrence. Patients were left with watchful waiting and anxiety, knowing the odds were against them.
That chapter of oncology history ended on May 31, 2026, when the New England Journal of Medicine published the results of LIBRETTO-432 — a global Phase III trial led by Professor Yi-Long Wu of Guangdong Provincial People’s Hospital that changed everything overnight.
What Is RET Fusion-Positive Lung Cancer?
RET fusion-positive NSCLC is a rare but distinct molecular subtype of lung cancer in which the RET gene abnormally fuses with another gene, producing a hyperactive protein that drives uncontrolled cell growth. This mutation occurs in only 1–2% of all NSCLC patients, making it one of the rarest actionable drivers in lung cancer.
While the targeted drug selpercatinib (Retevmo) had already been approved for advanced or metastatic RET fusion-positive NSCLC based on the landmark LIBRETTO-001 trial, its role in the adjuvant (post-surgery) setting remained entirely untested. Early-stage patients who underwent curative resection still faced recurrence rates exceeding 35% within two years — with no targeted option to reduce that risk.
The LIBRETTO-432 Trial: Design and Results
LIBRETTO-432 was a global, multicenter, randomized, double-blind, placebo-controlled Phase III trial that enrolled 151 patients with stage IB to IIIA RET fusion-positive NSCLC who had completed definitive therapy (surgery or radiotherapy) with curative intent. Patients were randomized 1:1 to receive either selpercatinib or placebo for up to 3 years.
The primary endpoint — investigator-assessed event-free survival (EFS) in stage II–IIIA patients — produced results that stunned the oncology community:
- Stage II–IIIA patients: 2-year EFS was 92% with selpercatinib vs. 61% with placebo (HR 0.17; 95% CI 0.06–0.51; P<0.001) — an 83% reduction in recurrence, progression, or death.
- All patients (IB–IIIA): 2-year EFS was 94% vs. 70% (HR 0.16; P<0.001) — an 84% reduction in events.
Blinded independent central review confirmed the investigator-assessed findings. Three deaths occurred during the study — all in the placebo group, all from disease progression.
Safety and Tolerability
Selpercatinib demonstrated a manageable safety profile consistent with its known profile in advanced disease. The most common grade ≥3 adverse events were elevated alanine aminotransferase (17%) and aspartate aminotransferase (19%), which were generally manageable with dose adjustments. Only 17% of patients discontinued treatment due to adverse events, and most side effects were reversible upon cessation.
This safety profile is particularly notable for an adjuvant therapy, where patients are disease-free and quality of life considerations carry enormous weight. The tolerability data suggest that the benefit-risk equation strongly favors selpercatinib in this curative-intent setting.
A Third Landmark After ADAURA and ALINA
LIBRETTO-432 represents Professor Wu’s seventh publication in the NEJM and his third groundbreaking adjuvant targeted therapy trial, following the paradigm-shifting ADAURA study (osimertinib for EGFR-mutant NSCLC) and ALINA study (alectinib for ALK-fusion NSCLC). Together, these three trials have fundamentally restructured the adjuvant treatment landscape for molecularly defined NSCLC subtypes.
The significance extends beyond RET: these results underscore the critical importance of comprehensive biomarker testing at diagnosis. Only by identifying RET fusions, EGFR mutations, and ALK fusions can patients be matched to the adjuvant targeted therapies that now offer them the best chance at cure.
Implications for Global Lung Cancer Guidelines
LIBRETTO-432 is expected to immediately reshape clinical practice guidelines worldwide. Key implications include:
- Mandatory RET testing for all early-stage NSCLC patients, alongside EGFR and ALK
- Selpercatinib as the new standard of care for adjuvant treatment of RET fusion-positive NSCLC
- Validation of the targeted adjuvant paradigm for yet another molecular subtype, reinforcing precision medicine as the backbone of post-surgical lung cancer care
- Hope for rare cancer patients globally — demonstrating that even ultra-rare subtypes (1–2% prevalence) can attract the investment and trial infrastructure needed to deliver curative-intent therapies
Guangdong Provincial People’s Hospital, through its Guangdong Lung Cancer Institute, continues to lead the world in designing and executing practice-changing lung cancer trials. For international patients seeking access to cutting-edge lung cancer care, this institution represents a cornerstone of innovation in thoracic oncology.
Sources
- Wu Y-L, Hochmair M, Yang Y, et al. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2026 May 31. DOI: 10.1056/NEJMoa2602628
- Guangdong Provincial People’s Hospital. “吴一龙教授重磅研究第七次登顶《新英格兰医学杂志》，重塑早期RET阳性肺癌治愈新希望.” June 3, 2026. Official news release
- ClinicalTrials.gov. LIBRETTO-432 (NCT04819100). NCT04819100
- Drilon A, Subbiah V. “Targeted Therapy for RET Fusion-Positive NSCLC: From Advanced to Early Stage.” NEJM Editorial, 2026.